Farmas USA

SRRA

Esto otro me anima tambien , pues el comprador sabe bastante de donde se metio..

The buyer, Sierra Oncology Inc. (NASDAQ: SRRA) of Vancouver, B.C., is led by  Nick Glover, who was CEO of YM BioSciences. That is the one-drug company that Gilead (NASDAQ: GILD) bought in 2013 as it tried to diversify from HIV drugs into cancer and other conditions.

"The company is uniquely positioned to advance momelotinib towards potential registration with several members of the Sierra senior management team having played key roles in the development of momelotinib from its discovery through to Phase 3 clinical trials," Glover said in a statemen

HZNP

Citing first mover advantage, Goldman Sachs analyst Dana Flanders is "confident" in his sales forecast for Horizon Pharma's (NASDAQ:HZNP) Krystexxa (pegloticase) despite the potential threat from Selecta Biosciences' (NASDAQ:SELB) SEL-212. Updated data from an ongoing mid-stage study will be presented at ACR in October.
Both are uricase treatments but Selecta says SEL-212 is the only one that avoids immunogenicity.
Krystexxa has been on the U.S. market since September 2010.
Previously: Selecta Biosciences' SEL-212 shows positive effect in mid-stage gout study (June 15)

TEVA

Dentro otra vez, al precio que sali 24.10, pero con menos cromos,, 500

Edito:

NVAX

Fura a 1.37  +6%  250$

tu has visto la vela semana que esta pintando TEVA?

y el patrón Three Black Crows en diario?

solo digo .. eh?

Si, lo veo,, pero no quiero estar fuera y como cada vez entiendo menos :))

Habra news en septiembre y solo es un 1er paquete.. y si hace falta, a LP :))

Tenía un precio en la cabeza, en el que quería salir la última vez e intentare conseguirlo... ( 29.30)

Gracias Framus por tu opinión y tus aportaciones...

Mientras casi todas las muestras bajan, RGLS no hace más que subir. Ciro ya debe estar en Las Maldivas tomándose unos mojitos, jeje

NVAX

Vuelvo a entrar a 1.31  4k cromos.

NVCR otra vez vuela libre